乳腺浸润性微乳头状癌的临床病理特征及预后影响因素OA
Clinicopathological features and prognostic factors of breast invasive micropapillary carcinoma
目的 探讨乳腺浸润性微乳头状癌(IMPC)的临床病理特征及生存情况,比较单纯型与混合型IMPC患者的临床病理特征及无瘤生存(DFS)和总生存(OS),并以IMPC占比75%为界进一步分析IMPC比例对预后的影响.方法 回顾性分析2005年1月至2025年10月中山大学孙逸仙纪念医院收治的230例乳腺IMPC患者的临床病理及随访资料.微乳头状成分占浸润性癌成分100%者为单纯型IMPC(104例),混有其他浸润性癌成分为混合型IMPC(126例);同时以IMPC占比75%为界,分为IMPC≤75%组(96例)和IMPC>75%组(134例).比较各组患者的临床病理特征及DFS和OS的影响因素.结果 单纯型IMPC与混合型IMPC在ER阳性率上差异有统计学意义.总人群5年DFS率为76.2%,10年OS率为67.8%.单纯型与混合型IMPC的5年DFS率分别为67.1%和82.5%(P=0.066),10年OS率分别为61.4%和73.8%(P=0.352).IMPC≤75%组与 IMPC>75%组的 5年 DFS率(82.4%vs.70.7%)及 10年 OS率(79.1%vs.63.0%)差异均无统计学意义.多因素分析显示,TNM分期(HR=7.320,95%CI:3.473~15.428,P<0.001)和内分泌治疗(HR=0.391,95%CI:0.166~0.919,P=0.031)是 DFS的影响因素;TNM 分期是 OS的独立影响因素(HR=6.628,95%CI:2.407~18.251,P<0.001).结论 单纯型IMPC患者的5年DFS率及10年OS率在数值上均低于混合型IMPC患者,但两组DFS、OS的差异均无统计学意义.临床实践中应重视TNM分期评估,并对激素受体阳性患者积极考虑内分泌治疗以改善DFS.
Objective To investigate the clinicopathological features and survival of invasive micro-papillary carcinoma(IMPC)of the breast.We compared pure-type IMPC with mixed-type IMPC in clini-copathological characteristics,disease-free survival(DFS),and overall survival(OS),and further as-sessed the prognostic impact of a 75%IMPC proportion threshold.Methods We retrospectively reviewed the clinicopathological and follow-up data of 230 patients with breast IMPC treated at Sun Yat-sen Memo-rial Hospital,Sun Yat-sen University,from January 2005 to October 2025.Pure-type IMPC was defined as a micropapillary component accounting for 100%of the invasive carcinoma(n=104);mixed-type IMPC was defined as IMPC admixed with other invasive carcinoma components(n=126).Patients were also stratified by a 75%threshold into an IMPC≤75%group(n=96)and an IMPC>75%group(n=134).Clinicopathological features and factors influencing DFS and OS were compared between the groups.Results The ER positivity rate differed significantly between pure-type and mixed-type IMPC.The overall 5-year DFS rate was 76.2%,and the 10-year OS rate was 67.8%.The 5-year DFS rates were 67.1%and 82.5%for pure-type and mixed-type IMPC,respectively(P=0.066);the 10-year OS rates were 61.4%and 73.8%(P=0.352).The 5-year DFS rates(82.4%vs.70.7%)and 10-year OS rates(79.1%vs.63.0%)did not differ significantly between the IMPC≤75%and IMPC>75%groups.Multivariable analysis showed that TNM stage(HR=7.320,95%CI:3.473~15.428,P<0.001)and endocrine therapy(HR=0.391,95%CI:0.166~0.919,P=0.031)were independent factors for DFS,and TNM stage(HR=6.628,95%CI:2.407~18.251,P<0.001)was an independent factor for OS.Conclusion Although the 5-year DFS and 10-year OS rates were numerically lower in pure-type than in mixed-type IMPC,neither difference was statistically significant.In clinical practice,TNM stage assessment should be emphasized,and endocrine therapy should be actively considered for hormone receptor-positive patients to improve DFS.
柴洁;丁林潇潇;王丽丽;陈韬;王君妍;蔡阳阳
中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120
医药卫生
浸润性微乳头状癌乳腺癌临床病理特征预后影响因素
invasive micropapillary carcinomabreast cancerclinicopathological characteristicsprognosisinfluencing factors
《岭南现代临床外科》 2026 (4)
207-214,8
国家自然科学基金项目(82271793825735938257347982203141)广州市科技计划项目(SL2023A03J011502024A03J11952025A03J4194)中国抗癌协会-HER-2靶点中国科研基金(CORP-239-S10)逸仙临床研究培育项目(SYS-Q-202101)逸仙临床研究5010计划(SYS-5010-202308、SYS-5010-202409)中山大学5010计划项目(81000-13130007)广东省乳腺疾病临床医学研究中心(2023B110005)国家科技重大专项(2024ZD05198002024ZD0519805)逸仙科研启航项目(SYSQH-II-2026-06)中国抗癌协会临床研究基金会(CETS-DSSCORP239-055)
评论